Screener
MapLight Therapeutics, Inc. MPLT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,188 | $3,289 |
| Accrued expenses | 10,175 | 12,049 |
| Lease liability - current | 920 | 891 |
| Total current liabilities | 14,283 | 16,229 |
| Lease liability - noncurrent | 4,671 | 4,911 |
| Total liabilities | 18,954 | 21,140 |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s accrued expenses?
- MapLight Therapeutics, Inc. (MPLT) reported accrued expenses of $10.18M in Q1 2026.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about MapLight Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude